Levis MJ - Search Results

1

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.

Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Perl AE, et al. Among authors: levis mj. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. Blood Cancer J. 2022. PMID: 35637252 Free PMC article.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

4

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963 Free article.

5

FLT3: ITDoes matter in leukemia.

Levis M, Small D. Levis M, et al. Leukemia. 2003 Sep;17(9):1738-52. doi: 10.1038/sj.leu.2403099. Leukemia. 2003. PMID: 12970773 Review.

6

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Zheng R, et al. Blood. 2004 Mar 1;103(5):1883-90. doi: 10.1182/blood-2003-06-1978. Epub 2003 Oct 30. Blood. 2004. PMID: 14592841 Free article.

7

Novel FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Expert Opin Investig Drugs. 2003 Dec;12(12):1951-62. doi: 10.1517/13543784.12.12.1951. Expert Opin Investig Drugs. 2003. PMID: 14640939 Review.

8

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

9

Small molecule FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Curr Pharm Des. 2004;10(11):1183-93. doi: 10.2174/1381612043452604. Curr Pharm Des. 2004. PMID: 15078134 Review.

10

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

Levis M, Pham R, Smith BD, Small D. Levis M, et al. Blood. 2004 Aug 15;104(4):1145-50. doi: 10.1182/blood-2004-01-0388. Epub 2004 May 4. Blood. 2004. PMID: 15126317 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

221 results

Search Page